Nilotinib Clonmel

Nilotinib, the active ingredient in Nilotinib Clonmel, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It selectively blocks BCR‑ABL tyrosine kinase, including the T315I mutation, and is indicated for the treatment of chronic myeloid leukemia in its chronic, accelerated, and blast phases in adult patients.

The product is manufactured in the European Union and meets applicable quality standards. GNH USA supplies Nilotinib Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib is used in the management of chronic myeloid leukemia, a myeloproliferative neoplasm driven by BCR‑ABL tyrosine kinase activity. - Chronic phase chronic myeloid leukemia: achieves disease control by reducing leukemic cell proliferation. - Accelerated phase chronic myeloid leukemia: slows disease progression and improves hematologic response. - Blast phase chronic myeloid leukemia: provides targeted therapy aimed at inducing remission.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Elevated liver enzymes: increased ALT or AST levels. - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be watery. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - QT interval prolongation: risk of cardiac arrhythmia, may be life‑threatening. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe hepatotoxicity: marked liver injury requiring medical intervention.

When prescribing nilotinib, clinicians should observe several precautionary measures to minimize risk. - Cardiac monitoring: obtain baseline ECG and periodically assess QT interval. - Liver function: monitor transaminases before initiation and during therapy. - Blood glucose: check fasting glucose as hyperglycemia may develop. - Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors. - Pregnancy: contraindicated; ensure effective contraception for women of childbearing potential. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Nilotinib interacts with several medicines; awareness of these interactions helps maintain therapeutic effectiveness and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nilotinib exposure and toxicity. - QT‑prolonging agents (e.g., amiodarone): additive risk of arrhythmia. - Antacids containing aluminum or magnesium: reduce nilotinib absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may lower nilotinib plasma levels. - Warfarin: may require more frequent INR monitoring. - St. John’s wort: potential reduction in nilotinib efficacy.